Your browser doesn't support javascript.
loading
The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang, Jae-Hwi; Janker, Florian; De Meester, Ingrid; Arni, Stephan; Borgeaud, Nathalie; Yamada, Yoshito; Gil Bazo, Ignacio; Weder, Walter; Jungraithmayr, Wolfgang.
Afiliación
  • Jang JH; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Janker F; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • De Meester I; Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
  • Arni S; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Borgeaud N; Department of Visceral Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Yamada Y; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Gil Bazo I; Department of Oncology, University Hospital Navarra, Pamplona, Spain.
  • Weder W; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Jungraithmayr W; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Carcinogenesis ; 40(2): 324-334, 2019 04 29.
Article en En | MEDLINE | ID: mdl-30698677
ABSTRACT
CD26/dipeptidyl peptidase 4 (DPP4) is a transmembrane protein which is expressed by various malignant cells. We found that the expression of CD26/DPP4 was significantly higher in lung adenocarcinoma samples in our own patient cohort compared to normal lung tissue. We therefore hypothesize that the inhibition of CD26/DPP4 can potentially suppress lung cancer growth. The CD26/DPP4 inhibitor vildagliptin was employed on Lewis Lung Carcinoma (LLC) cell line and a human lung adenocarcinoma (H460) cell line. Two weeks after subcutaneous injection of tumor cells into C57BL/6 and CD1/nude mice, the size of LLC and H460 tumors was significantly reduced by vildagliptin. Immunohistochemically, the number of macrophages (F4/80+) and NK cells (NKp46+) was significantly increased in vildagliptin-treated tumor samples. Mechanistically, we found in vitro that lung cancer cell lines expressed increased levels of surfactant protein upon vildagliptin treatment thereby promoting the pro-inflammatory activity of macrophages. By the depletion of macrophages with clodronate and by using NK cell deficient (IL-15-/-) mice, tumors reversed to the size of controls, suggesting that indeed macrophages and NK cells were responsible for the observed tumor-suppressing effect upon vildagliptin treatment. FACS analysis showed tumor-infiltrating NK cells to express tumor necrosis-related apoptosis-inducing ligand (TRAIL) which induced the intra-cellular stress marker γH2AX. Accordingly, we found upregulated γH2AX in vildagliptin-treated tumors and TRAIL-treated cell lines. Moreover, the effect of vildagliptin-mediated enhanced NK cell cytotoxicity could be reversed by antagonizing the TRAIL receptor. Our data provide evidence that the CD26/DPP4-inhibitor vildagliptin reduces lung cancer growth. We could demonstrate that this effect is exerted by surfactant-activated macrophages and NK cells that act against the tumor via TRAIL-mediated cytotoxicity.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Dipeptidil Peptidasa 4 / Proliferación Celular / Inhibidores de la Dipeptidil-Peptidasa IV / Vildagliptina / Neoplasias Pulmonares / Macrófagos Límite: Animals / Humans / Male Idioma: En Revista: Carcinogenesis Año: 2019 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Dipeptidil Peptidasa 4 / Proliferación Celular / Inhibidores de la Dipeptidil-Peptidasa IV / Vildagliptina / Neoplasias Pulmonares / Macrófagos Límite: Animals / Humans / Male Idioma: En Revista: Carcinogenesis Año: 2019 Tipo del documento: Article País de afiliación: Suiza